This site is intended for healthcare professionals only

Sponsored resources


This promotional session has been initiated, fully funded and reviewed by Ipsen and is intended for UK healthcare professionals. Products and brands will be mentioned.


Best approach to hormone therapy in prostate cancer

This promotional video presentation was originally broadcast on 18 May 2021. Please note that the speaker(s) are not able to answer questions from attendees watching the video on-demand.

Prescribing information and adverse event reporting for Decapeptyl® SR can be found here:

Company profile

Ipsen UK & Ireland are a core part of Ipsen’s global biopharmaceutical business and are driven by the belief that patients don’t have time to wait. We have a biotech mindset couples with pharmaceutical capabilities and have invested in a robust business presence that spans the early stages of R&D (Abingdon, Oxford) through to in-house manufacturing (Wrexham, Wales & Dublin, Ireland) so we can effectively deliver on our promise to UK & Irish patients. As part of this investment, we employ over 900 people across our four sites, including our commercial headquarters in Bath Road, Slough.

Our business focuses on oncology, rare diseases and neurosciences to create innovative therapies in areas of high unmet medical need. Ipsen works across a diverse oncology portfolio, which includes prostate cancer, neuroendocrine tumours and renal cell carcinoma. Our licensed medicines and R&D are all focused on improving the lives of patients, hoping to bring real value to the patient and healthcare community along every step of the treatment pathway.

Click to view prescribing information for Decapeptyl SR (triptorelin) 3mg, Decapeptyl SR (triptorelin) 11.25mg, and Decapeptyl SR (triptorelin) 22.5mg

To request a rep please email:

Job code: TRI-UK-004569 | Date of preparation: May 2021

© Copyright Omniamed Communications. All Rights Reserved 108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom